Description

Glepaglutide acetate (also known as Glepaglutide or ZP-1848) is a synthetic long-acting GLP-2 analogue designed to enhance intestinal growth, absorption, and barrier function. In clinical studies for short bowel syndrome, Glepaglutide significantly increased intestinal fluid and nutrient absorption and reduced parenteral support requirements. Its acetate salt form improves peptide stability and solubility, making it ideal for laboratory models of gastrointestinal regeneration and inflammatory bowel conditions.

Manufactured in a GMP-compliant facility to ensure high-quality standards and reproducibility for research applications. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Glepaglutide acetate functions as a GLP-2 receptor agonist, promoting intestinal mucosal regeneration, increasing nutrient and fluid absorption, and strengthening gut barrier integrity. It is especially useful in models of short bowel syndrome and intestinal failure, where it has demonstrated reductions in parenteral support needs and improvements in absorption metrics. Its acetate salt form further enhances stability for in-study administration. All use is intended only for laboratory research purposes.

Side Effects (For Reference Only in Models)

In laboratory settings, Glepaglutide acetate may cause mild changes in cellular proliferation or fluid dynamics in gut epithelial cultures. No systemic toxicity data exists—for laboratory research use only—not for clinical or human/animal use.

Disclaimer

Glepaglutide acetate is provided strictly for laboratory research use only. It is not approved for human or veterinary utilization. All handling must comply with institutional safety and compliance protocols.